Coya Therapeutics (NASDAQ:COYA – Get Free Report) is expected to be issuing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.36) per share and revenue of $0.13 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.15 million. On average, analysts expect Coya Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Coya Therapeutics Trading Up 2.9%
NASDAQ COYA traded up $0.13 during trading hours on Tuesday, hitting $4.56. The company’s stock had a trading volume of 54,335 shares, compared to its average volume of 194,671. The company has a market capitalization of $106.96 million, a PE ratio of -3.97 and a beta of 0.51. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75. The company’s 50-day simple moving average is $4.88 and its two-hundred day simple moving average is $4.66.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Coya Therapeutics
Institutional Investors Weigh In On Coya Therapeutics
Several large investors have recently made changes to their positions in the business. Jane Street Group LLC raised its stake in shares of Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after purchasing an additional 13,176 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in Coya Therapeutics during the second quarter worth about $119,000. JPMorgan Chase & Co. bought a new stake in Coya Therapeutics in the third quarter worth about $28,000. Dauntless Investment Group LLC boosted its stake in Coya Therapeutics by 199.5% in the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after acquiring an additional 101,932 shares during the last quarter. Finally, Citadel Advisors LLC grew its position in shares of Coya Therapeutics by 51.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after acquiring an additional 22,120 shares during the period. 39.75% of the stock is owned by hedge funds and other institutional investors.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.
Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.
Featured Articles
- Five stocks we like better than Coya Therapeutics
- Apple’s AI Strategy Looks Different—Will It Pay Off?
- The AI Chip Stock Making a Quiet Move Toward Dominance
- Why Walmart and Amazon Could Be the Market’s Most Complementary Mega-Caps
- Dodging Deutsche Telekom: T-Mobile’s Strategic Win
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
